Rivaara Immune Private Limited
About Rivaara Immune Private Limited
Data last updated:
Rivaara Immune Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the oncology clinics and cancer treatment segment of the healthcare sector. It was incorporated on 27 August 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U85200MH2019PTC329805. Its GSTIN is 27AAJCR7813A1ZH (Maharashtra).
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹1 Lakh. It is led by directors Mayank Jayantilal Shah and Siddharth Bharat Daftary.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 17th Floor Hoechst House Nariman Point, Mumbai, Maharashtra, India – 400021.
Company details
Contact details
Rivaara Immune Private Limited's registered office is in Mumbai, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address17th Floor Hoechst House Nariman Point, Mumbai, Maharashtra, India – 400021
- IndustryHealthcare, Oncology Clinics & Cancer Treatment
To see the full contact details of Rivaara Immune Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Rivaara Immune Private Limited
FY 2025 filings availableRivaara Immune Private Limited reported revenue of ₹1,550 (up 761% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue rose 761% in the latest year, though over three years it has declined at a compounded annual rate (CAGR) of 47%. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | |||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | |||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | |||||
| Net Profit Margin | |||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Rivaara Immune Private Limited, buy the company report.
Board of directors of Rivaara Immune Private Limited
Rivaara Immune has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mayank Jayantilal Shah Also directs: Advy Biolucent Private Limited | Director | 26 Dec 2023 | 2 Years 10 Months | Current |
| Siddharth Bharat Daftary | Director | 27 Aug 2019 | 7 Years 2 Months | Current |
Peer comparison
Rivaara Immune Private Limited is compared with the 6 companies closest to it by revenue in the Healthcare industry (Oncology Care), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| HMZ Laboratories Private Limited | ₹66,410 (FY 2022) | Gurgaon, Haryana, India | ||||
| Guru Harikrishn Foundation | ₹41,555 (FY 2025) | -62.0% | New Delhi, Delhi, India | |||
| Suryoday Cancer and Research Private Limited | ₹38,981 (FY 2025) | 388157.0% | Nashik, Maharashtra, India | |||
| D.S. Research & Hospital Institute Private Limited | ₹30,000 (FY 2025) | Kolkata, West Bengal, India | ||||
| Jhansi Cancer Hospital and Research Institute Private Limited | ₹10,000 (FY 2025) | Jhansi, Uttar Pradesh, India | ||||
| Rivaara Immune Private Limitedthis company | ₹1,550 (FY 2025) | 761.0% | Mumbai, Maharashtra, India | |||
| Nangal Cancer Hospital & Research Institute Private Limited | ₹945 (FY 2025) | Bikaner, Rajasthan, India |
To see the full peer comparison of Rivaara Immune Private Limited, buy the company report.
Auditor
Rivaara Immune Private Limited is audited by Gyaneshwar Kataram & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Gyaneshwar Kataram & Associates | FY 2023 | 124286W |
Shareholding
The shareholding of Rivaara Immune Private Limited is on record for 4 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Rivaara Immune Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Rivaara Immune Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Rivaara Immune Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Rivaara Immune has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAJCR7813A1ZH | Maharashtra | Active | 27 Jun 2022 |
To see the full GST registrations and return filing status of Rivaara Immune Private Limited, buy the company report.
Recent activity
Rivaara Immune Private Limited has 4 board changes on record since 2019: 2 appointments and 2 cessations. The latest: Mayank Jayantilal Shah ceased to be Additional Director on 29 Sep 2024.
Frequently asked questions
Rivaara Immune is an active private limited company based in Mumbai, Maharashtra, India. The company works in oncology clinics and cancer treatment, within the healthcare industry. It was incorporated on 27 August 2019 (7+ years old) and is registered under CIN U85200MH2019PTC329805.
Rivaara Immune has 2 current directors:
- Mayank Jayantilal Shah - Director
- Siddharth Bharat Daftary - Director
The latest financial statements of Rivaara Immune on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Rivaara Immune is 27AAJCR7813A1ZH, registered in Maharashtra.
The CIN (Corporate Identification Number) of Rivaara Immune is U85200MH2019PTC329805. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Rivaara Immune was incorporated on 27 August 2019, making it 7+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Rivaara Immune by revenue are HMZ Laboratories Private Limited, Guru Harikrishn Foundation, Suryoday Cancer and Research Private Limited, D.S. Research & Hospital Institute Private Limited, Jhansi Cancer Hospital and Research Institute Private Limited and 1 more, all in the Healthcare industry (Oncology Care).
Mayank Jayantilal Shah ceased to be Additional Director on 29 Sep 2024. Mayank Jayantilal Shah was appointed as Director on 26 Dec 2023. Bharat Vinod Daftary ceased to be Director on 07 Dec 2023. Rivaara Immune has 4 board changes on record in total.
The registered office of Rivaara Immune is at 17th Floor Hoechst House Nariman Point, Mumbai, Maharashtra, India – 400021.
Rivaara Immune operates in the healthcare industry, in the oncology clinics and cancer treatment segment.
Rivaara Immune can be reached at its registered office: 17th Floor Hoechst House Nariman Point, Mumbai, Maharashtra, India – 400021.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
